@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms
ConditionIntracranial Aneurysm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Geneva
About this trial
The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA).
The SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database.
The purpose for populating the database are to:
* Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as markers the following: genetics factors, microbiota, environmental factors, congenital factors (ie: cerebrovascular anatomical variants), transcriptomics signature, proteomics signature,shape characteristics, haemodynamics characteristics. * Screen for and evaluate prognostic factors of outcome regarding different management strategies including watchful observation, microsurgical treatment, endovascular treatment or any combination thereof. * Implement and evaluate patient-specific management protocols integrating all available information. * Evaluate the impact of the database and use of tools to improve care, reduce costs, support knowledge discovery and promote new industrial developments.
Eligibility criteria
Qualifiers
able to provide consent or, in the event that a patient is incapable of providing consent, that a person is legally authorized to do so on behalf of the patient according to legal and ethical requirements of the country where the clinical centre is located.
must have an angiographically proven intracranial aneurysm (MRA< CTA< DSA accepted).The determination of SAH requires the presence of a subarachnoid haemorrhage be verified on CT or by lumbar puncture.
Disqualifiers
failure of a candidate to contribute clinical data,
refusal to provide informed consent.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
20,000 Participants
are grouped into 4 trial groupsSponsors and collaborators
University Hospital, Geneva
Lead sponsor
University of Geneva, Switzerland
Collaborator
Klinik Hirslanden, Zurich
Collaborator
Source ClinicalTrials.gov